Search clinical trials for: TYK2/JAK1 inhibitor

Total 67986 results

Emma Guttman
Pfizer

Completed

Dual JAK1/TYK2 Inhibitor for Cicatricial Alopecia

Cicatricial Alopecia

United States
Priovant Therapeutics, Inc.

Recruiting

A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis (VALOR)

Dermatomyositis

United States, Belgium, Germany, Hungary, Israel, Italy, Netherlands, Portugal, Korea, Republic of, Bulgaria, Poland, Romania, Czechia, Taiwan, Chile, Mexico, Turkey, Serbia, Spain, United Kingdom, Canada
Prof Curdin Conrad
Centre Hospitalier Universitaire Vaudois

Not yet recruiting

TYK2 Inhibition in Paradoxical Psoriasis (TYPP)

Psoriasis

Switzerland
Pfizer

Completed

JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis (JADE TEEN)

Atopic Dermatitis

Spain, United States, Taiwan, Germany, China, Hungary, Australia, Czechia, Japan, Latvia, Poland, United Kingdom, Mexico, Italy
Ventyx Biosciences, Inc

Active, not recruiting

VTX958 for the Treatment of Moderately to Severely Active Crohn's Disease (Harmony-CD)

Crohn Disease

United States, Australia, Brazil, Bulgaria, Canada, Czechia, Georgia, Germany, Hungary, Israel, Italy, Lithuania, Moldova, Republic of, Poland, Slovakia
Yale University
Pfizer

Recruiting

Janus Kinase Inhibition in Sarcoidosis

Sarcoidosis

United States
Centre Hospitalier Universitaire de Nice

Recruiting

Vitiligo Treatment by Targeting TYK2 Mediated Responses (ViTYK)

Vitiligo, Generalized

France
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure

Severe Aplastic Anemia | Single Lineage Cytopenias, T-LGL | Hypoplastic MDS

United States
Ventyx Biosciences, Inc

Terminated

VTX958 Versus Placebo for the Treatment of Active Psoriatic Arthritis (Tranquility-PsA)

Psoriatic Arthritis

United States, Bulgaria, Czechia, Germany, Hungary, Poland, Spain
Philipps University Marburg Medical Center

Completed

Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS (RuXoCoil)

COVID | ARDS, Human

Germany
Incyte Corporation

Completed

Safety of Itacitinib in Combination With Corticosteroids for Treatment of Steroid-Naive Acute Graft-Versus-Host Disease in Japanese Subjects

Acute Graft-versus-host Disease

Japan
University of Utah
Karyopharm Therapeutics Inc

Active, not recruiting

Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors (ESSENTIAL)

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States
Ventyx Biosciences, Inc

Terminated

VTX958 Versus Placebo for the Treatment of Moderate to Severe Psoriasis (Serenity PsO)

Psoriasis

Poland, United States, Canada
Incyte Corporation

Withdrawn

A Study to Evaluate the Safety and Efficacy of Itacitinib in Moderate to Severe Ulcerative Colitis

Moderate to Severe Ulcerative Colitis
Pfizer

Terminated

Study to Evaluate PF-04965842 in Patients With Moderate to Severe Psoriasis

Plaque Psoriasis

United States, Canada
Incyte Corporation

Terminated

Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung Transplantation

Bronchiolitis Obliterans Syndrome

United States, Belgium, Canada
Bristol-Myers Squibb

Active, not recruiting

A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis

Psoriasis

United States, Australia, Canada, Japan, United Kingdom
Jinnah Hospital

Completed

Efficacy of Oral Tofacitinib in Moderate to Severe Alopecia Areata, Totalis and Universalis at Tertiary Care Hospital, Karachi.

Alopecia Areata | Alopecia Totalis | Alopecia Universalis

Pakistan
Incyte Corporation

Completed

A Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa

Hidradenitis Suppurativa

United States
Eli Lilly and Company

Completed

Oral Baricitinib (LY3009104)Treatment in Japanese Participants With Active Rheumatoid Arthritis on Background Methotrexate Therapy

Arthritis, Rheumatoid

Japan
Incyte Corporation

Terminated

Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric Subjects

Acute Graft-versus-host Disease

United States, Spain, France, Italy, United Kingdom, Germany
National Cancer Institute (NCI)

Active, not recruiting

Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

Chronic Graft vs Host Disease | Chronic Graft-Versus-Host Disease

United States
University of Michigan Rogel Cancer Center

Terminated

Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders

Lymphoproliferative Disorders | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Lymphoma, T-Cell, Cutaneous | Chronic Lymphocytic Leukemia | Lymphoplasmacytic Lymphoma | Lymphoma, T-Cell, Peripheral

United States
The Lymphoma Academic Research Organisation
Novartis

Completed

A Phase II Study of Oral JAK1/JAK2 Inhibitor INC424 in Adult Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma (HIJAK)

Hodgkin's Lymphoma

France, Belgium
Sichuan University

Unknown

Ruxolitinib Plus LVP in Patients With R/R ETP-ALL

Acute T Cell Leukemia
Karyopharm Therapeutics Inc

Active, not recruiting

A Study to Evaluate Safety and Efficacy of Selinexor Versus Treatment of Physician's Choice in Participants With Previously Treated Myelofibrosis

Myelofibrosis

Spain, China, Poland, United States, France, Greece, Italy
Pfizer

Completed

A Study to Determine the Effects of PF-04965842 on Midazolam PK in Healthy Volunteers

Phase 1

Belgium
Bristol-Myers Squibb

Recruiting

A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (POETYK SLE-2)

Systemic Lupus Erythematosus

United States, Australia, Taiwan, Japan, Spain, Singapore, Poland, Greece, Hungary, Mexico, Puerto Rico, Brazil, Argentina, United Kingdom, Chile, Peru, Turkey, Czechia, Portugal, India, Thailand, Bulgaria
Bristol-Myers Squibb

Recruiting

A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-1)

Systemic Lupus Erythematosus

United States, Korea, Republic of, Brazil, China, Germany, Italy, France, Mexico, Poland, Puerto Rico, Argentina, Canada, Colombia, Hong Kong, Romania, Portugal, Turkey, Ireland, Peru, India, Lithuania, Bulgaria, Slovakia
Eli Lilly and Company
Incyte Corporation

Completed

A Study in Participants With Rheumatoid Arthritis on Background Methotrexate Therapy

Arthritis, Rheumatoid

Hungary, Romania, United States, Czechia, Croatia, Poland, Ukraine, Mexico, India
The Children's Hospital of Zhejiang University...
First Affiliated Hospital, Sun Yat-Sen University; Tongji Hospital; Qilu Hospital... and other collaborators

Recruiting

Cytokine Guided Risk Stratification and Treatment in Pediatric Hemophagocytic Lymphohistiocytosis

Cytokine Storm | Hemophagocytic Lymphohistiocytoses

China
AstraZeneca

Terminated

A Phase I Study of AZD1480 in Patients With Advanced Solid Malignancies and Advanced Hepatocellular Carcinoma in the Escalation Phase,Non-Small Cell Lung Cancer(NSCLC) and Non-smokers With Lung Metastasis and Gastric Cancer and Solid Tumour in the Expansion Phase.

Gastric Cancer | Advanced Solid Malignancies | Solid Tumour | Child-Pugh A to B7 Advanced Hepatocellular Carcinoma | EGFR and/or ROS Mutant NSCLC | Lung Metastasis Carcinoma

Korea, Republic of
Pfizer

Completed

A Study to Determine the Effects of PF-04965842 on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Subjects

Healthy Females

United States
Incyte Corporation

Completed

A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Lymphoma

United States
Merck Sharp & Dohme LLC
GOG Foundation; European Network of Gynaecological Oncological Trial Groups...

Not yet recruiting

A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

Cervical Cancer
Assiut University

Not yet recruiting

Serum Cystatin C for Early Detection of Acute Kidney Injury After Primary Percutaneous Coronary Intervention

Acute Kidney Injury
Merck Sharp & Dohme LLC

Not yet recruiting

A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001)

Neoplasm Metastasis
Lee's Pharmaceutical Limited

Not yet recruiting

Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer

Cervical Cancer
Merck Sharp & Dohme LLC

Not yet recruiting

Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)

Essential Thrombocythemia
Shanghai Chest Hospital
Novartis; Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; BeiGene

Not yet recruiting

Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC

KRAS Mutation-Related Tumors | Advanced Lung Cancer | Refractory Tumor

China
Memorial Sloan Kettering Cancer Center
TransThera Sciences

Recruiting

A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer

Prostate Cancer

United States
Coherus Biosciences, Inc.

Not yet recruiting

A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer (TRANSPARENT)

Nasopharyngeal Cancer Recurrent
Kocaeli City Hospital
Health Institutes of Türkiye (TUSEB)

Not yet recruiting

Effect of Sevoflurane and Desflurane on Heme Oxygenase-1 Expression in Elective Cholecystectomy

Cholecystitis, Chronic

Turkey
Alexandria University
Tanta University

Recruiting

Impact of Curcumin and Pentoxiphylline on Chronic Kidney Disease Patients (CKD)

Chronic Kidney Disease

Egypt
Stemline Therapeutics, Inc.

Not yet recruiting

A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy

Acute Myeloid Leukemia

United States
Peking Union Medical College Hospital

Recruiting

Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.

Marginal Zone Lymphoma

China
Ningbo No. 1 Hospital

Recruiting

First-line Treatment of PCNSL With the Combination of Orelabrutinib, Rituximab, and Methotrexate (ORM Regimen)

Primary Central Nervous System Lymphoma

China
Yongyong MA

Recruiting

Daratumumab/Daratumumab and Hyaluronidase-fihj in Combination With Pomalidomide and Dexamethasone for the Treatment of Patients With Newly Diagnosed AL Amyloidosis: a Prospective, Multicenter, Single-arm Study

Amyloid Light-chain Amyloidosis

China
Fondazione Policlinico Universitario Agostino Gemelli...

Recruiting

Markers of Favorable Response to Complement Inhibitors Therapy (OPTIMISE)

Myasthenia Gravis, Generalized

Italy
Jilin University

Not yet recruiting

Efficacy of Upadacitinib After NECS in Vitiligo

Vitiligo

Search clinical trials for: TYK2/JAK1 inhibitor

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Denmark

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations